‘White plague’ is on the rise in the US — it’s deadlier than Covid and becoming antibiotic resistant

10,260 tuberculosis cases were reported nationwide in provisional 2025 CDC data (967 in New York), with US cases rising since 2020 and reversing three decades of decline. Antibiotic resistance is increasing—589 US cases were resistant to at least one front-line drug in 2023—and the CDC estimates up to 13 million Americans living with latent TB (5–10% risk of progression), creating risks of wider transmission and more difficult, longer (6–9 month) treatment courses. Globally TB kills ~1.6 million people annually and remains preventable with early detection and treatment, highlighting potential public-health resource strain and the need for improved testing, treatment adherence, and infection-control measures.

Analysis

This resurgence should be framed as a slow-moving structural demand shock rather than a one-off headline event: a large dormant pool of infections plus rising drug resistance create multi-year market opportunities across diagnostics, specialty anti-infectives and built-environment upgrades. Expect testing volumes to front-load as public health agencies chase case-finding, then settle into elevated baseline screening and preventive therapy demand that supports durable reagent and platform revenue for molecular diagnostics suppliers.

Antibiotic resistance is the key second-order mechanism: it shifts spend from cheap generics to higher-priced, longer-duration salvage regimens and companion diagnostics, increasing per-patient revenue for companies that own the new molecular assays, oral TB drugs and adherence technologies. Municipal and institutional customers (corrections, shelters, public hospitals, school systems) will be large procurement drivers, creating lumpiness in sales but predictable multi-quarter contract flows; HVAC and filtration vendors will see capex tails tied to procurement cycles and municipal budgets.

Catalysts to watch in 6–36 months that change the investment map are: widescale rollouts of rapid molecular screening, regulatory approvals for shorter oral regimens, major federal/state funding infusions, or a vaccine approval/scale-up — any of which would compress time-on-drug and reduce total treatment cost per case. The market consensus appears to treat this as a transient public-health story; that underprices long-duration revenues and M&A risk into high-quality diagnostics and specialty pharma, while also underestimating downside credit stress in overstretched municipal healthcare systems as treatment complexity rises.

Key Decisions for Investors

• Buy Danaher (DHR), 6–18 month horizon. Rationale: Cepheid cartridge-style revenue exposure gives direct leverage to higher molecular TB testing volumes; use a collar or buy Jan-2027 LEAPs to cap downside. Risk/reward: limited downside to premium with 20–35% upside if testing volumes materialize and cartridge ASPs hold.
• Buy Johnson & Johnson (JNJ), 12–36 months. Rationale: Exposure to patented/newer anti-TB agents and attractive M&A/royalty optionality as big pharma consolidates specialty TB franchises. Risk/reward: conservative share buy with 15–30% upside vs single-digit downside; hedge with short healthcare beta if concerned about broad market pullbacks.
• Buy Honeywell (HON) or Carrier (CARR), 6–12 months. Rationale: Direct play on accelerated institutional HVAC/filtration capex from infection-control programs; enter on pullbacks and target municipal contract news as triggers. Risk/reward: modest multi-quarter re-rating (10–25%) if municipal procurement accelerates; downside limited to industrial cyclicality.
• Pair trade: Long DHR (or Roche RHHBY) / Short HCA Healthcare (HCA), 3–12 months. Rationale: Long diagnostics captures revenue upside from testing; short large hospital operator captures margin pressure from longer, more complex TB treatments and uncompensated care. Risk/reward: structure with equal dollar exposure; target 2:1 upside skew if diagnostics growth outpaces hospital margin recovery.